Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.
Valuation & Earnings
This table compares Enzon Pharmaceuticals and ProKidney’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Enzon Pharmaceuticals has higher revenue and earnings than ProKidney.
Volatility & Risk
Insider & Institutional Ownership
16.9% of ProKidney shares are held by institutional investors. 0.3% of Enzon Pharmaceuticals shares are held by insiders. Comparatively, 45.0% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Enzon Pharmaceuticals and ProKidney’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent ratings and price targets for Enzon Pharmaceuticals and ProKidney, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ProKidney has a consensus target price of $15.33, indicating a potential upside of 77.47%. Given ProKidney’s higher possible upside, analysts clearly believe ProKidney is more favorable than Enzon Pharmaceuticals.
Enzon Pharmaceuticals beats ProKidney on 5 of the 9 factors compared between the two stocks.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.